Company / Cash & Equivalents
Amphstar Pharmaceuticals, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$170.2M
FY2025
5-year range
$126.4M / $170.2M
FY2021-FY2025
Trend
+12.2%
vs FY2024
Sector context
#100 of 207
Health Care
What the data says
At $170M, Amphstar Pharmaceuticals, Inc.'s cash & equivalents ranks #100 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $66M in FY2017 to $170M in FY2025.
Based on SEC 10-K filings.
$170M in FY2025 with a 5-year CAGR of +12.9%.
Improved from $144M to $170M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +2.9%
- 5-Year CAGR
- +12.9%
- 10-Year CAGR
- -
Sector benchmark
#100 of 207 in Health CareTop 48% of 207This company $170.2M Sector average $669.5M
▼
-74.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 12.2% year-over-year.
- Ranks #100 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $170.2M | +12.2% |
| FY2024 | $151.6M | +5.1% |
| FY2023 | $144.3M | -7.6% |
| FY2022 | $156.1M | +23.5% |
| FY2021 | $126.4M | +36.4% |
| FY2020 | $92.6M | +25.7% |
| FY2019 | $73.7M | -14.7% |
| FY2018 | $86.3M | +31.6% |
| FY2017 | $65.6M | -9.3% |
| FY2016 | $72.4M | +9.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026